Theseus Pharmaceuticals Inc 's ROA from the third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Theseus Pharmaceuticals Inc 's ROA in the third quarter of 2023?
Theseus Pharmaceuticals Inc recorded a cumulative net loss of $-57 million during 12 months ending in the third quarter of 2023, resulting in a negative return on assets (ROA) of -23.8%.

However, within the Healthcare sector 408 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2023 quarter, so far to 3959, from total ROA ranking in the second quarter of 2023 at 4028.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter	(Sep 30 2022) III. Quarter
Y / Y Total Assets Change	0.15 %	2148.58 %	1913.73 %	7484.48 %	3682.21 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-57	-58	-55	-51	-46
Return On Assets (TTM)	-23.8 %	-24.33 %	-30.39 %	-42.21 %	-70.55 %
THRX's Total Ranking	# 3959	# 4028	# 4131	# 4727	# 4184
Total Assets (TTM) in million	232	242	253	224	232
Seq. Total Assets Change	-4.09 %	-4.18 %	12.67 %	-3.28 %	2053.39 %
Seq. Net Income Change	-	-	-	-	-

THRX's 5 Years Annual ROA >> Back to THRX Management Effectiveness >> Compare THRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 160
Sector	# 409
Overall	# 3891

Return On Assets Statistics
High	Average	Low
-18.3 %	-21.68 %	-24.27 %
(Jun 30 2022)		(Jun 30 2023)

Financial Statements
Theseus Pharmaceuticals Inc 's Assets	$ 232 million	THRX's Balance sheet
Theseus Pharmaceuticals Inc 's Income	$ -14 million	Quarterly THRX's Income Statement
THRX's Income by Division		See THRX's Income by Division

Annual Return On Assets	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY	FY	FY
Y / Y Total Assets Change	7450.68 %	-	-	-	-
Total Assets in million	223	3	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-51	-27	0	0	0
Annual Return On Assets	-22.66 %	-923.19 %	-	-	-

THRX's 5 Years Annual ROA >> Back to THRX Management Effectiveness >> Compare THRX ROA to its Competitors

More Return On Assets Ratios
THRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
THRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for THRX's Competitors
Subscribers only: Roa for Theseus Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for THRX's Customers

You may also want to know
THRX's Roi	THRX's Inventory Turnover Ratio	THRX's Growth Rates	THRX's Dividend Comparisons
	THRX's Profitability Ratios	THRX's Asset Turnover Ratio	THRX's Dividend Growth
THRX's Roe	THRX's Valuation Ratios	THRX's Financial Strength Ratios	THRX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2023, within Healthcare Sector

ROA

Date modified: 2026-06-22T14:32:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.